LSDs are inherited metabolic disorders caused by a deficiency in lysosomal enzymes. Enzyme replacement therapy (ERT) is used to treat certain LSDs.
In connection with this agreement, both the companies will undertake certain experiments at their own expense and Shire has been granted certain options to obtain a license to biOasisâ€™ Transcend technology on mutually agreeable terms.
Under the terms of the agreement, scientists from biOasis and Shire will collaborate on a program designed to evaluate the potential of Transcend to deliver an enzyme to the brain.
Rob Hutchison, CEO of biOasis Technologies, said: "biOasis is pleased to enter into this agreement with Shire as it fits ideally within biOasis' strategy and deals with our core technology. The work we have done to date on Transcend and the milestones we have achieved all support driving us to agreements such as this one we are announcing today. The work will start immediately and over the coming months we are looking forward to working with Shire to successfully achieve the objectives set out in the research work plan."
biOasis Technologies is a biopharmaceutical company engaged in the development and commercialization of products for the diagnosis and treatment of neurological diseases and disorders.
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.